Media ReleasesImpediMed

View All ImpediMed News


ImpediMed - Receipt of $1.8 Million R&D Tax Incentive Refund


ImpediMed Limited (ASX.IPD) today announced the receipt of a $1.8 million cash refund related to the R&D Tax Incentive.

The cash rebate is related to expenditure on eligible Australian and international R&D activities during the 2021 financial year.

For more information, download the attached PDF.

Download this document

Are you a 708 sophisticated investor?

A sophisticated investor is defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

They are eligible to receive information regarding wholesale investment opportunities that are not available to regular or retail investors.

Please subscribe if you would like to be alerted to these types of opportunities.